Thorne HealthTech, Inc. (THRN) Tops Q2 EPS by 9c

Thorne HealthTech, Inc. (NASDAQ: THRN) reported Q2 EPS of $0.15, $0.09 better than the analyst estimate of $0.06. Revenue for the quarter came in at $72.7 million versus the consensus estimate of $68.41 million.

GUIDANCE:

Thorne HealthTech, Inc. sees FY2023 EPS of $0.26-$0.32, versus the consensus of $0.29. Thorne HealthTech, Inc. sees FY2023 revenue of $285-290 million, versus the consensus of $282 million.

For earnings history and earnings-related data on Thorne HealthTech, Inc. (THRN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance